“People often think about the genome as the blueprint of the organism, but that’s not really correct,” Steven Quake told reporters at a Science press briefing earlier this week. “The genome is more of a parts list, because every cell type uses different parts.” Quake is president of the Chan Zuckerberg Biohub Network, and professor of bioengineering and applied physics at Stanford University.
There is a project management joke that the first 90% of a project takes 90% of the time, whereas the last 10% of the project takes the other 90% of the time.
There is a project management joke that the first 90% of a project takes 90% of the time, whereas the last 10% of the project takes the other 90% of the time.
DUBLIN – Fans of “His Dark Materials” and the “Book of Dust,” Philip Pullman’s series of fantasy novels set in Oxford, U.K. and more remote corners of the earth, are familiar with alethiometers. In the hands of a highly select number of characters, these complex, compass-like devices can interrogate a mysterious substance called “dust” – an elementary particle associated with consciousness – and provide trusted answers to the most crucial questions.
A genome-wide association study has identified 290 genetic variants, including a wide range of DNA damage response genes, that are associated with age at menopause.
Researchers at Yale University have described what they have called a “data sanitization tool,” enabling them to strip personal identifiers out of functional genomics data while preserving their usefulness for research.
The Genotype-Tissue Expression (GTEx) project, a multiyear, multi-institutional attempt to catalog how expression quantitative trait loci (eQTL) and splicing quantitative trait loci (sQTL) affect protein levels, reported data from its final phase in 15 papers in the Sept, 10, 2020, online issues of the Science and Cell family of journals, as well as in Genome Biology.
HONG KONG South Korea's biopharmaceutical venture Genome & Co. Ltd. recently secured KRW30.2 billion (US$25.2 million) in series C investment with an IPO and global clinical trial plans for next year.
A team at the Broad Institute of Harvard and MIT has developed a genome editing method that could, in principle, correct 90% of the roughly 75,000 currently known genomic changes that are associated with genetic diseases.
HONG KONG – South Korea's 3billion Inc., a rare genetic diseases diagnosis startup based in Seoul, has secured ?11.4 billion (US$9.6 million) in a series B investment. The company was founded in 2016 as a spinoff of Macrogen Inc., a Seoul-based genetic sequencing biotech, and raised ?3 billion in a series A funding last year.